CN116531380B - 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 - Google Patents
用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺Info
- Publication number
- CN116531380B CN116531380B CN202310479983.0A CN202310479983A CN116531380B CN 116531380 B CN116531380 B CN 116531380B CN 202310479983 A CN202310479983 A CN 202310479983A CN 116531380 B CN116531380 B CN 116531380B
- Authority
- CN
- China
- Prior art keywords
- oxo
- dihydropyridazine
- carboxamide
- pyridin
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155406 | 2017-02-09 | ||
| EP17155406.6 | 2017-02-09 | ||
| EP17202882 | 2017-11-21 | ||
| EP17202882.1 | 2017-11-21 | ||
| CN201880024008.8A CN110678459B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
| PCT/EP2018/052627 WO2018146010A1 (en) | 2017-02-09 | 2018-02-02 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880024008.8A Division CN110678459B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116531380A CN116531380A (zh) | 2023-08-04 |
| CN116531380B true CN116531380B (zh) | 2025-11-07 |
Family
ID=61188789
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310479983.0A Active CN116531380B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
| CN202310485656.6A Active CN116554152B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
| CN201880024008.8A Active CN110678459B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310485656.6A Active CN116554152B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
| CN201880024008.8A Active CN110678459B (zh) | 2017-02-09 | 2018-02-02 | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 |
Country Status (39)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810366WA (en) * | 2016-05-25 | 2018-12-28 | Bayer Pharma AG | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
| US12522594B2 (en) | 2017-02-09 | 2026-01-13 | Deutsches Krebsforschungszentrum | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| CN112724256B (zh) * | 2019-10-28 | 2022-09-16 | 中国农业大学 | 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用 |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| BR112022007837A2 (pt) | 2019-12-16 | 2022-07-05 | Bayer Ag | Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer |
| JP2023515128A (ja) | 2020-02-26 | 2023-04-12 | ジャガー セラピューティクス ピーティーイーリミテッド | Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体 |
| BR112022019387A2 (pt) * | 2020-03-27 | 2022-11-16 | Dong A St Co Ltd | Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CN114539221B (zh) * | 2020-11-27 | 2026-08-07 | 苏州泽璟生物制药股份有限公司 | 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用 |
| CN114685426B (zh) * | 2020-12-28 | 2026-05-26 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| WO2023043753A1 (en) * | 2021-09-14 | 2023-03-23 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
| US20230190961A1 (en) | 2021-10-20 | 2023-06-22 | University Of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| CN119948035A (zh) | 2022-10-03 | 2025-05-06 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323297A (zh) * | 1998-08-14 | 2001-11-21 | 日本农药株式会社 | 哒嗪酮衍生物 |
| WO2008080056A2 (en) * | 2006-12-21 | 2008-07-03 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JP2000119257A (ja) * | 1998-08-14 | 2000-04-25 | Nippon Nohyaku Co Ltd | ピリダジノン誘導体 |
| US6358964B1 (en) | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
| JP4233868B2 (ja) | 2000-09-18 | 2009-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリダジノンおよびトリアジノン化合物類ならびにそれらの医薬用途 |
| FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE102004055998A1 (de) | 2004-11-19 | 2006-05-24 | Rheinische Friedrich-Wilhelms-Universität Bonn | Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie |
| CA2586420A1 (en) | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| WO2006082952A1 (ja) | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
| US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| AR057986A1 (es) | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| EP2023910B1 (en) | 2006-05-03 | 2013-06-19 | Symrise AG | Ah receptor antagonists |
| GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
| DE102006054205A1 (de) | 2006-11-15 | 2008-05-29 | Rheinische Friedrich-Wilhelms Universität | Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit |
| RU2483072C2 (ru) | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US20130338201A1 (en) | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| US10314810B2 (en) | 2010-07-27 | 2019-06-11 | Trustees Of Boston University | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| WO2015143164A1 (en) | 2014-03-19 | 2015-09-24 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
| SG11201810366WA (en) | 2016-05-25 | 2018-12-28 | Bayer Pharma AG | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
| US12522594B2 (en) | 2017-02-09 | 2026-01-13 | Deutsches Krebsforschungszentrum | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| EP3713926B1 (en) | 2017-11-21 | 2023-06-07 | Bayer Aktiengesellschaft | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists |
| EP3713931B1 (en) | 2017-11-21 | 2025-03-05 | Deutsches Krebsforschungszentrum | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| WO2019101642A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| US11524944B2 (en) | 2017-11-21 | 2022-12-13 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors |
| CN113015526A (zh) | 2018-09-19 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 螺环2,3-二氢-7-氮杂吲哚化合物及其用途 |
| EP3880198A4 (en) | 2018-11-14 | 2022-08-10 | The Broad Institute, Inc. | ARYHYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS |
| EP4013508A1 (en) | 2019-08-12 | 2022-06-22 | Bayer Aktiengesellschaft | [1,2,4]triazolo[1,5-c]quinazolin-5-amines |
| WO2021074279A1 (en) | 2019-10-16 | 2021-04-22 | Bayer Aktiengesellschaft | Spiro-fused tricyclic map4k1 inhibitors |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
-
2018
- 2018-02-02 US US16/485,049 patent/US12522594B2/en active Active
- 2018-02-02 DK DK18703958.1T patent/DK3580211T3/da active
- 2018-02-02 GE GEAP202115183A patent/GEAP202115183A/en unknown
- 2018-02-02 CA CA3052718A patent/CA3052718A1/en active Pending
- 2018-02-02 GE GEAP201815183A patent/GEP20217281B/en unknown
- 2018-02-02 CR CR20190364A patent/CR20190364A/es unknown
- 2018-02-02 LT LTEP18703958.1T patent/LT3580211T/lt unknown
- 2018-02-02 SI SI201830192T patent/SI3580211T1/sl unknown
- 2018-02-02 ES ES18703958T patent/ES2847162T3/es active Active
- 2018-02-02 JO JOJO/P/2019/0193A patent/JOP20190193B1/ar active
- 2018-02-02 JP JP2019542502A patent/JP7128826B2/ja active Active
- 2018-02-02 PL PL18703958T patent/PL3580211T3/pl unknown
- 2018-02-02 RS RS20210096A patent/RS61401B1/sr unknown
- 2018-02-02 AU AU2018217860A patent/AU2018217860B2/en active Active
- 2018-02-02 MY MYPI2019004509A patent/MY198510A/en unknown
- 2018-02-02 SG SG11201907232XA patent/SG11201907232XA/en unknown
- 2018-02-02 MA MA47447A patent/MA47447B1/fr unknown
- 2018-02-02 CU CU2019000073A patent/CU24564B1/es unknown
- 2018-02-02 MX MX2019009571A patent/MX2019009571A/es unknown
- 2018-02-02 CN CN202310479983.0A patent/CN116531380B/zh active Active
- 2018-02-02 CN CN202310485656.6A patent/CN116554152B/zh active Active
- 2018-02-02 BR BR112019016497A patent/BR112019016497A2/pt not_active Application Discontinuation
- 2018-02-02 HU HUE18703958A patent/HUE053191T2/hu unknown
- 2018-02-02 UA UAA201909559A patent/UA124507C2/uk unknown
- 2018-02-02 KR KR1020197025958A patent/KR102627266B1/ko active Active
- 2018-02-02 CN CN201880024008.8A patent/CN110678459B/zh active Active
- 2018-02-02 WO PCT/EP2018/052627 patent/WO2018146010A1/en not_active Ceased
- 2018-02-02 EP EP18703958.1A patent/EP3580211B1/en active Active
- 2018-02-02 HR HRP20210143TT patent/HRP20210143T1/hr unknown
- 2018-02-02 PE PE2019001570A patent/PE20191496A1/es unknown
- 2018-02-05 TW TW107104035A patent/TWI770113B/zh active
- 2018-02-09 UY UY0001037606A patent/UY37606A/es not_active Application Discontinuation
-
2019
- 2019-08-04 IL IL268469A patent/IL268469B/en unknown
- 2019-08-08 PH PH12019501846A patent/PH12019501846A1/en unknown
- 2019-08-08 SA SA519402422A patent/SA519402422B1/ar unknown
- 2019-08-09 CO CONC2019/0008684A patent/CO2019008684A2/es unknown
- 2019-08-09 NI NI201900085A patent/NI201900085A/es unknown
- 2019-08-09 CL CL2019002255A patent/CL2019002255A1/es unknown
- 2019-08-09 DO DO2019000206A patent/DOP2019000206A/es unknown
- 2019-08-12 EC ECSENADI201957713A patent/ECSP19057713A/es unknown
- 2019-09-06 ZA ZA2019/05902A patent/ZA201905902B/en unknown
-
2021
- 2021-01-28 CY CY20211100070T patent/CY1124484T1/el unknown
-
2022
- 2022-08-12 US US17/819,602 patent/US11795164B2/en active Active
-
2025
- 2025-11-26 US US19/402,587 patent/US20260098036A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323297A (zh) * | 1998-08-14 | 2001-11-21 | 日本农药株式会社 | 哒嗪酮衍生物 |
| WO2008080056A2 (en) * | 2006-12-21 | 2008-07-03 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11795164B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| CN109863140B (zh) | 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺 | |
| US11304946B2 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | |
| US11591311B2 (en) | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides | |
| US11524944B2 (en) | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | |
| HK1218256A1 (zh) | 使用mek抑制劑的方法 | |
| HK40097687B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| HK40098354A (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| HK40097687A (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| HK40020738A (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| HK40020738B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EA037978B1 (ru) | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40097687 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |